This is a working overview of LC-MS, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-22 and is reviewed periodically as new material appears.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Marketed for research use in some regions. |
| Human clinical data | Limited or absent | Most evidence is from cell and animal studies. |
| Primary proposed pathway | HGF/c-Met signaling | Angiotensin IV-related activity also reported. |
| Common study models | Rodent neurons and behavioral tasks | Results may not translate directly to humans. |
| Key uncertainty | Bioavailability and brain exposure | Questions remain about absorption and target engagement. |
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
He noted that the final episode, which features archival footage of Cloud's character Fezco, also acted as a tribute to Cloud and said, "It was a way of honoring Angus and saying a prayer for the future".
The strength and direction of these fields are the same regardless of the size of a wound. Healing of skin wounds is a complex process involving the cooperation of various elements of the body, such as platelets, immune cells, epithelial cells, and fibroblasts. This process is coordinated largely by chemical signals, but there is evidence that electrotaxis plays an additional role in directing specific cell types toward the site of an injury. During the proliferation phase of recovery, keratinocytes move toward the cathodal side of the EFs occurring around and injury, bringing them toward the edge of the wound. In fact, in vitro experimentation found that application of physiological strength EFs could override other signals and guide cells to migrate towards or even away from a wound depending on the direction of the field, regardless of chemical factors. EFs have also experimentally been found to influence cell migration in human umbilical vein cells, dermal fibroblasts, and myofibroblasts.
=== Metabolism === Ribose is referred to as the "molecular currency" because of its involvement in intracellular energy transfers. For example, nicotinamide adenine dinucleotide (NAD), flavin adenine dinucleotide (FAD), and nicotinamide adenine dinucleotide phosphate (NADP) all contain the d-ribofuranose moiety. They can each be derived from d-ribose after it is converted to d-ribose 5-phosphate by the enzyme ribokinase. NAD, FAD, and NADP act as electron acceptors in biochemical redox reactions in major metabolic pathways including glycolysis, the citric acid cycle, fermentation, and the electron transport chain.
Psychological Depression Suicidal ideation Nightmares Apathy, anhedonia, or dysphoria Anxiety, especially social anxiety Decreased alertness, awareness, and wakefulness Impaired attention and concentration Fatigue Malaise Drowsiness Restlessness Cognitive and memory impairment Derealization or depersonalization, as well as mild psychosis Sexual dysfunction including impaired libido, desire, and drive Physiological Dizziness, lightheadedness, or vertigo Miosis or pupil constriction Xerostomia or dry mouth Gastrointestinal disturbances such as diarrhea or constipation Headache or migraine Myalgia or muscle aches, arthralgia or joint pain, or paresthesia ("pins and needles") Restless legs syndrome (RLS) Parkinsonian symptoms such as muscle tremors, rigidity, hypokinesia, or balance or postural instability Akathisia, ataxia, dyskinesia, as well as even tardive dyskinesia or dystonia Bell's palsy or facial paralysis Sexual dysfunction Hyperprolactinemia Gynecomastia in males, amenorrhoea or absence of menstrual cycles in females Bradycardia Hypotension Orthostatic hypotension Hepatitis, hepatotoxicity, or liver dysfunction or damage Pancreatitis Warm autoimmune hemolytic anemia or deficiency in red blood cells (RBCs) Myelotoxicity or bone marrow suppression, potentially leading to thrombocytopenia, blood platelet deficiency, leukopenia, or white blood cell deficiency Hypersensitivity (e.g., lupus erythematosus, myocarditis, or pericarditis) Lichenoid reactions (e.g., skin lesions or rashes) Pallor
Sources: en.wikipedia.org
In addition to the classical nuclear AR, bicalutamide has been assessed at the membrane androgen receptors (mARs) and found to act as a potent antagonist of ZIP9 (IC50 = 66.3 nM), whereas it does not appear to interact with GPRC6A. The affinity of bicalutamide for the AR is relatively low as it is approximately 30 to 100 times lower than that of DHT, which is 2.5- to 10-fold as potent as an AR agonist as testosterone in bioassays and is the main endogenous ligand of the receptor in the prostate gland. However, typical clinical dosages of bicalutamide result in circulating levels of the drug that are thousands of times higher than those of testosterone and DHT, allowing it to powerfully prevent them from binding to and activating the receptor. This is especially true in the case of surgical or medical castration, in which testosterone levels in the circulation are approximately 95% reduced and DHT levels in the prostate gland are about 50 to 60% reduced. In women, levels of testosterone are substantially lower (20- to 40-fold) than in men, so much smaller doses of bicalutamide (e.g., 25 mg/day in the hirsutism studies) are necessary. Blockade of the AR by bicalutamide in the pituitary gland and hypothalamus results in prevention of the negative feedback of androgens on the hypothalamic–pituitary–gonadal axis (HPG axis) in males and consequent disinhibition of pituitary luteinizing hormone (LH) secretion. This, in turn, results in an increase in circulating LH levels and activation of the gonadal production of testosterone and by extension production of estradiol.
During starvation or while consuming a low-carb/ketogenic diet, the liver produces ketones. Ketones are needed as fatty acids cannot pass the blood-brain barrier, blood glucose levels are low and glycogen reserves depleted. Ketones also convert to acetyl-CoA faster than fatty acids. After the ketones convert to acetyl-CoA in a process known as ketolysis, it enters the citric acid cycle to produce ATP by oxidative phosphorylation. The longer that the person's glycogen reserves have been depleted, the higher the blood concentration of ketones, typically due to starvation or a low carb diet (βHB 3 - 5 mM). Prolonged high-intensity aerobic exercise, such as running 20 miles, where individuals "hit the wall" can create post-exercise ketosis; however, the level of ketones produced are smaller (βHB 0.3 - 2 mM).
Some border zones, referred to as border vistas, are composed of legally mandated cleared space between two areas of foliage located at an international border intended to provide a clear demarcation line between two jurisdictions. Border vistas are most commonly found along undefended international boundary lines, where border security is not as much of a necessity and a built barrier is undesired, and are a treaty requirement for certain borders. An example of a border vista is a 6-metre (20-foot) cleared space around unguarded portions of the Canada–United States border. Similar clearings along the border line are provided for by many international treaties. For example, the 2006 border management treaty between Russia and China provides for a 15-metre (49-foot) cleared strip along the two nations' border. In 2024, Egypt announced that they are building a buffer zone on the Egypt-Gaza border.
persistence 1. The tendency of a moving cell to continue moving in the same direction as previously; that is, even in isotropic environments, there inevitably still exists an inherent bias by which, from instant to instant, cells are more likely not to change direction than to change direction. Averaged over long periods of time, however, this bias is less obvious and cell movements are better described as a random walk. 2. The ability of some viruses to remain present and viable in cells, organisms, or populations for very long periods of time by any of a variety of strategies, including retroviral integration and immune suppression, often in a latent form which replicates very slowly or not at all.
In many MHD systems, most of the electric current is compressed into thin, nearly two-dimensional ribbons termed current sheets. These can divide the fluid into magnetic domains within which the currents are relatively weak. Current sheets in the solar corona are thought to be between a few meters and a few kilometers thick, which is quite thin compared to the magnetic domains, which are thousands to hundreds of thousands of kilometers across. Another example occurs in the Earth's magnetosphere, where current sheets separate topologically distinct domains, isolating most of the Earth's ionosphere from the solar wind.
Sources: en.wikipedia.org
The associated enzymes are subject to regulation via feedback inhibition and/or repression at the genetic level. As is typical in highly branched metabolic pathways, additional regulation at each branch point of the pathway. This type of regulatory scheme allows control over the total flux of the aspartate pathway in addition to the total flux of individual amino acids. The aspartate pathway uses L-aspartic acid as the precursor for the biosynthesis of one-fourth of the building block amino acids.
This company, founded in 1948 by Tony Amato and his wife, Sally, found a permanent home at 319 Bowery next to the former CBGB and afforded many young singers the opportunity to hone their craft in full-length productions with a cut-down orchestration. It closed on May 31, 2009, when Tony Amato retired.
=== Huntington's disease === Huntington's disease is a hyperkinetic movement basal ganglia disease caused by lack of normal inhibitory inputs from medium spiny neurons of the basal ganglia. This poses the opposite effects of those associated with Parkinson's disease, including inappropriate activation of upper motor neurons. As with the GABAergic mechanisms observed in relation to Parkinson's disease, a GABA agonist injected into the substantia nigra pars reticulata decreases inhibition of upper motor neurons, resulting in ballistic involuntary motor movements, similar to symptoms of Huntington's disease.
=== Suppression of crystallization === Antiscalants contain molecules that can complex with metal ions present in the water, preventing them from participating in scale formation reactions. Phosphonates and polyphosphates are particularly effective in sequestering calcium, magnesium, and other metal ions.
Sources: en.wikipedia.org
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.
Preclinical research has focused on synaptic growth, cognitive performance in animals, and HGF/c-Met signaling. These are experimental findings, not established treatments.
Legality varies by country and intended use. It is commonly sold as a research chemical, and sales for human consumption may be restricted. Local regulations should be checked.
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.